The clinical trial conducted by Sun Yat-sen University explores the pharmacokinetic-guided administration of pembrolizumab in advanced non-small cell lung cancer (NSCLC). Given the established role of pembrolizumab as a standard therapy in NSCLC, this study may provide insights into optimizing dosing strategies, potentially enhancing efficacy and safety profiles. The trial's completion and its focus on pharmacokinetics could position Sun Yat-sen University favorably in the competitive landscape of immuno-oncology, particularly as personalized medicine continues to gain traction. The findings may also influence future treatment guidelines and reimbursement strategies, impacting market access for pembrolizumab and similar agents.